A company was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to treat patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). MMAE is a potent anti-cancer drug that is a CYP3A substrate and a weak competitive CYP3A inhibitor
Phoenix Cloud (フェニックス・クラウド)の詳細はお気軽にお問合せください
Phoenix Cloud is a cloud-based solution that enables research teams to manage the entire process from NCA to population modeling using the industry gold standard software of the Phoenix platform.
お問合せはこちら



